Lotus Pharmaceutical Registers Increased Q1 Growth; Will Pursue Acquisitions, Product Diversification
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Beijing-based Lotus Pharmaceuticals will further diversify its product portfolio and make acquisitions in the long term, the company said at the back of announcing increased growth figures over the first quarter ended March 31
You may also be interested in...
Chinese Regulators Provide Fast-track Review Status For Lotus On Modified Version Of AstraZeneca's Bambec
SHANGHAI - Lotus Pharmaceuticals, a Beijing-based drug maker and distributor of Western medicines, announced April 29 that the company had received clinical trial approval for its innovative anti-asthma drug R-Bambuterol Hydrochloride (laevo-bambuterol) from China's State FDA
Chinese Regulators Provide Fast-track Review Status For Lotus On Modified Version Of AstraZeneca's Bambec
SHANGHAI - Lotus Pharmaceuticals, a Beijing-based drug maker and distributor of Western medicines, announced April 29 that the company had received clinical trial approval for its innovative anti-asthma drug R-Bambuterol Hydrochloride (laevo-bambuterol) from China's State FDA
Lotus Set To Build New Manufacturing Facility, Pharma Park In Inner Mongolia
SHANGHAI - Lotus Pharmaceuticals, a Beijing-based drug maker and a distributor of Western medicines, is channeling RMB 180 million ($26.3 million) into establishing a new manufacturing base and pharmaceutical park in Inner Mongolia, according to company executives
Need a specific report? 1000+ reports available
Buy Reports